Recently, the KEYNOTE-091 study also demonstrated that pembrolizumab in combination with or without adjuvant chemotherapy significantly improved disease-free survival in patients with stage IB-IIIA NSCLC after surgical resection, regardless of PD-L1 expression level. This evidence concerns the gene CD274 and non-small cell lung carcinoma.